From Name:
From Email:
To Name:
To Email:

Optional Message:

New-generation DES Better Than Older Stents Over 10 Years, Regardless of Polymer Type

from TCTMD

New-generation drug-eluting stents provide better clinical outcomes than earlier devices over 10 years of follow-up, results from the ISAR-TEST 4 trial confirm, but a potential late added benefit of using a biodegradable versus durable polymer was not borne out. Two new-generation stents — the everolimus-eluting Xience (Abbott) and sirolimus-eluting Yukon Choice PC (Translumina Therapeutics) — reduced rates of MACE and all-cause death compared with the first-generation sirolimus-eluting Cypher (Cordis) during extended follow-up, Sebastian Kufner, MD, reported at the American Heart Association 2018 Scientific Sessions. more

Powered by MultiBriefs
7701 Las Colinas Blvd., Ste. 800, Irving, TX 75063